Loading…
RARE
ULTRAGENYX PHARMACEUTICAL INC.NasdaqResearch view
Healthcare · Pharmaceutical Preparations · SEC EDGAR FY 2025-12-31
Price history
Interactive · live data via TradingView🔒 Click to interact · scroll moves the page
Snapshot
SEC EDGAR · FY 2025-12-31SectorHealthcare
Income$-575.0M
Sales$673.0M
Book/sh$-0.81
Cash/sh$4.27
Dividend TTM$0.00
Payout—
Employees—
IPO—
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.
Revenue & Earnings — fiscal year
$351.4M
2021
$363.3M
2022
$434.0M
2023
$560.0M
2024
$673.0M
2025
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $351.4M | $363.3M | $434.0M | $560.0M | $673.0M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-381.7M | $-648.9M | $-569.0M | $-536.0M | $-535.0M |
| Net Income | $-454.0M | $-707.4M | $-607.0M | $-569.0M | $-575.0M |
| Diluted EPS | $-6.70 | $-10.12 | $-8.25 | $-6.29 | $-5.83 |
| Operating Cash Flow | $-338.7M | $-380.5M | $-475.0M | $-414.0M | $-466.0M |
| Free Cash Flow | $-411.8M | $-496.6M | $-519.0M | $-421.0M | $-472.0M |
Deep dive
Computed from the SEC EDGAR multi-year statementsOperating leverage — margins
GrossOperatingNet
Follow the news. Follow the move.
RARE story timeline
Company updates and connected market context, with the dated price move attached.
1
Stories
1
Direct
COMMUNITY · $RARE0 theses
POST YOUR TAKE →Related Stocks
Loading peers…
Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.